MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
2.610
-0.220 (-7.77%)
At close: Mar 6, 2026, 4:00 PM EST
2.660
+0.050 (1.92%)
After-hours: Mar 6, 2026, 7:57 PM EST
MannKind Employees
As of December 31, 2025, MannKind had 592 total employees, including 591 full-time and 1 part-time employees. The number of employees increased by 185 or 45.45% compared to the previous year.
Employees
592
Change (1Y)
185
Growth (1Y)
45.45%
Revenue / Employee
$589,470
Profits / Employee
$9,904
Market Cap
804.14M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| KalVista Pharmaceuticals | 270 |
| Xencor | 250 |
| Omeros | 202 |
| Sana Biotechnology | 194 |
| Kura Oncology | 192 |
| CytomX Therapeutics | 121 |
| Annexon | 99 |
MNKD News
- 2 days ago - MannKind Announces Settlement of Convertible Senior Notes - GlobeNewsWire
- 3 days ago - MannKind to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 9 days ago - MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 16 days ago - MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 17 days ago - MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 26 days ago - MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) - GlobeNewsWire
- 4 weeks ago - 2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion - Seeking Alpha